Literature DB >> 12972028

The role of EVI1 in normal and leukemic cells.

Silvia Buonamici1, Soumen Chakraborty, Vitalyi Senyuk, Giuseppina Nucifora.   

Abstract

One of the genes associated with both murine and human myeloid leukemia is EVI1 (ecotropic viral integration 1 site). EVI1 was first identified as a common locus of retroviral integration in myeloid tumors found in AKXD mice. The exact mechanism by which EVI1 induces leukemogenesis is not clear. Studies of the function of EVI1 in the bone marrow and in cell lines have shown that the inappropriate expression of EVI1 prohibits terminal differentiation of the bone marrow progenitor cells in granulocytes and erythroid cells, but strongly favors hematopoietic differentiation along the megakaryocytic lineage. We summarize recent data showing that EVI1 is a complex transcription factor with multiple functions, and this complexity is further demonstrated by the ability of EVI1 to interact with coactivators and corepressors and to abrogate cellular response to cytokines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972028     DOI: 10.1016/s1079-9796(03)00159-1

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  24 in total

1.  Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells.

Authors:  Boris Calmels; Cole Ferguson; Mikko O Laukkanen; Rima Adler; Marion Faulhaber; Hyeoung-Joon Kim; Stephanie Sellers; Peiman Hematti; Manfred Schmidt; Christof von Kalle; Keiko Akagi; Robert E Donahue; Cynthia E Dunbar
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

2.  The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.

Authors:  E Vasyutina; J M Boucas; J Bloehdorn; C Aszyk; G Crispatzu; M Stiefelhagen; A Breuer; P Mayer; C Lengerke; H Döhner; D Beutner; A Rosenwald; S Stilgenbauer; M Hallek; A Benner; M Herling
Journal:  Leukemia       Date:  2015-05-04       Impact factor: 11.528

3.  The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features.

Authors:  Marion Eveillard; Jacques Delaunay; Steven Richebourg; Laurence Lodé; Richard Garand; Soraya Wuillème; François Duhoux; Hélène Antoine-Poirel; Catherine Godon; Marie C Béné
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

Review 4.  Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases.

Authors:  David A Williams; Adrian J Thrasher
Journal:  Stem Cells Transl Med       Date:  2014-03-28       Impact factor: 6.940

5.  Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1.

Authors:  Grant A Challen; Nathan C Boles; Stuart M Chambers; Margaret A Goodell
Journal:  Cell Stem Cell       Date:  2010-03-05       Impact factor: 24.633

6.  Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells.

Authors:  Yang Du; Nancy A Jenkins; Neal G Copeland
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

7.  Correlations of common polymorphism of EVI-1 gene targeted by miRNA-206/133b with the pathogenesis of breast cancer.

Authors:  Tian-Yi Wang; Yin-Peng Huang; Ping Ma
Journal:  Tumour Biol       Date:  2014-06-17

Review 8.  Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy.

Authors:  Perry B Hackett; David A Largaespada; Kirsten C Switzer; Laurence J N Cooper
Journal:  Transl Res       Date:  2013-01-10       Impact factor: 7.012

9.  EVI1 induces myelodysplastic syndrome in mice.

Authors:  Silvia Buonamici; Donglan Li; Yiqing Chi; Rui Zhao; Xuerong Wang; Larry Brace; Hongyu Ni; Yogen Saunthararajah; Giuseppina Nucifora
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

10.  Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells.

Authors:  Marita Bosticardo; Amrita Ghosh; Yang Du; Nancy A Jenkins; Neal G Copeland; Fabio Candotti
Journal:  Mol Ther       Date:  2009-07-28       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.